Arbutus Biopharma Corp

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Other Events

Results of Operations and Financial Condition

Termination of a Material Definitive Agreement

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Other Events

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Other Events

Other Events

Other Events

Other Events

Results of Operations and Financial Condition

Other Events

Other Events

Results of Operations and Financial Condition

Termination of a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Other Events

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

06b

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Registration statement under Securities Act of 1933

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

No description available

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Roivant Sciences Ltd.

Roivant Sciences Ltd.

Arbutus Biopharma Corp

Arbutus Biopharma Corp

Nguyen Tuan

Sawhney Roger

Beardsley Robert A

Androski Lindsay

Whitefort Capital Management, LP

Arbutus Biopharma Corp

Arbutus Biopharma Corp

MORGAN STANLEY

Sawhney Roger

Beardsley Robert A

Two Seas Capital LP

Whitefort Capital Management, LP

Whitefort Capital Management, LP

Two Seas Capital LP

MORGAN STANLEY

Androski Lindsay

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

No description available

No description available

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

No description available

Correspondence with the SEC

No description available

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC